Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Literature DB >> 21960835

Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Helen S Te¹, Glenn Randall, Donald M Jensen.

Abstract

The current standard treatment for chronic hepatitis C consists of the combination of pegylated interferon and ribavirin. Although interferon is known to have potent antiviral, immunomodulatory, and anti-inflammatory activities against hepatitis C, the mechanism of ribavirin action against this virus is not clearly understood. This article will review proposed mechanisms of ribavirin activity, along with their supporting data, covering ribavirin's roles in the direct inhibition of hepatitis C viral replication, the inhibition of inosine monophosphate dehydrogenase, the induction of mutagenesis to the threshold of error catastrophe, and immunomodulation.

Entities: Chemical Disease

Keywords: Ribavirin; hepatitis C; inosine; ribonucleoside

Year: 2007 PMID： 21960835 PMCID： PMC3099343

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

69 in total

Review 1. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine.

Authors: H Tilg
Journal: Gastroenterology Date: 1997-03 Impact factor: 22.682

2. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

Authors: M E Cramp; S Rossol; S Chokshi; P Carucci; R Williams; N V Naoumov
Journal: Gastroenterology Date: 2000-02 Impact factor: 22.682

3. The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels.

Authors: R C Tam; K Ramasamy; J Bard; B Pai; C Lim; D R Averett
Journal: Antimicrob Agents Chemother Date: 2000-05 Impact factor: 5.191

4. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors: Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal: Nature Date: 2004-12-16 Impact factor: 49.962

5. Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets.

Authors: Sarah Gallois-Montbrun; Yuxing Chen; Hélène Dutartre; Magali Sophys; Solange Morera; Catherine Guerreiro; Benoit Schneider; Laurence Mulard; Joël Janin; Michel Veron; Dominique Deville-Bonne; Bruno Canard
Journal: Mol Pharmacol Date: 2003-03 Impact factor: 4.436

6. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.

Authors: J Martín; S Navas; J A Quiroga; M Pardo; V Carreño
Journal: Cytokine Date: 1998-08 Impact factor: 3.861

Review 7. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Authors: Jordan J Feld; Jay H Hoofnagle
Journal: Nature Date: 2005-08-18 Impact factor: 49.962

8. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription.

Authors: P Toltzis; K O'Connell; J L Patterson
Journal: Antimicrob Agents Chemother Date: 1988-04 Impact factor: 5.191

9. Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1.

Authors: L M Scheidel; V Stollar
Journal: Virology Date: 1991-04 Impact factor: 3.616

10. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase.

Authors: Nam V Vo; Kung-Chia Young; Michael M C Lai
Journal: Biochemistry Date: 2003-09-09 Impact factor: 3.162

41 in total

Review 1. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.

Authors: Gerson Dierley Keppeke; S John Calise; Edward K L Chan; Luis Eduardo C Andrade
Journal: World J Gastroenterol Date: 2016-02-14 Impact factor: 5.742

2. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

Authors: Kathleen B Schwarz; Regino P Gonzalez-Peralta; Karen F Murray; Jean P Molleston; Barbara A Haber; Maureen M Jonas; Philip Rosenthal; Parvathi Mohan; William F Balistreri; Michael R Narkewicz; Lesley Smith; Steven J Lobritto; Stephen Rossi; Alexandra Valsamakis; Zachary Goodman; Patricia R Robuck; Bruce A Barton
Journal: Gastroenterology Date: 2010-10-28 Impact factor: 22.682

Review 3. Hepatitis B and C.

Authors: Wikrom Karnsakul; Kathleen B Schwarz
Journal: Pediatr Clin North Am Date: 2017-06 Impact factor: 3.278

4. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex.

Authors: Alexander J Valvezan; Molly C McNamara; Spencer K Miller; Margaret E Torrence; John M Asara; Elizabeth P Henske; Brendan D Manning
Journal: JCI Insight Date: 2020-04-09

5. Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study.

Authors: Hanane Yousfi; Carole Cassagne; Stéphane Ranque; Jean-Marc Rolain; Fadi Bittar
Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191

Review 6. Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection.

Authors: Mariya Farooq; Abdul Waheed Khan; Bilal Ahmad; Moon Suk Kim; Sangdun Choi
Journal: Front Pharmacol Date: 2022-06-30 Impact factor: 5.988

7. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis.

Authors: Jing Hong Loo; Wen Xin Flora Xu; Jun Teck Low; Wei Xuan Tay; Le Shaun Ang; Yew Chong Tam; Prem Harichander Thurairajah; Rahul Kumar; Yu Jun Wong
Journal: World J Hepatol Date: 2022-06-27

8. Discontinuation of new hepatitis C drugs among Medicare patients.

Authors: Jeah Jung; Ping Du; Roger Feldman; Thomas Riley
Journal: Am J Manag Care Date: 2020-02 Impact factor: 2.229

9. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.

Authors: Juferdy Kurniawan; Rino Alvani Gani; Irsan Hasan; Andri Sanityoso Sulaiman; Cosmas Rinaldi A Lesmana; Chynthia Olivia Maurine Jasirwan; Kemal Fariz Kalista; Saut Horas Hatoguan Nababan; Steven Zulkifly
Journal: Indian J Gastroenterol Date: 2019-01-12

Review 10. Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi.

Authors: Lucie Peyclit; Hanane Yousfi; Jean-Marc Rolain; Fadi Bittar
Journal: Pharmaceuticals (Basel) Date: 2021-05-20